Acquisitions
Acquisitions completed from the 2024 financial year are distributed among the Group’s business areas as follows:
| Net Sales, | Number of | ||||
| Company | Country | Time | SEKm* | employees* | Business area |
| BonsaiLab S.L. | Spain | July, 2024 | 90 | 13 | Labtech |
| Edge Medical Ltd. | UK | April, 2025 | 90 | 20 | Medtech |
| 180 | 33 | ||||
| *Refers to conditions at the time of acquisition on a full-year basis. | |||||
On April 1, 2025, all shares in the UK company Edge Medical Ltd. were acquired. Edge Medical is a leading distributor in orthopedic surgery, spinal surgery, and neurology, with operations in the UK and Irish market. The company has an annual net sales of approximately GBP 8m with high margin and about 20 employees.
Preliminary purchase price allocation
The assets and liabilities included in the acquired business during the financial year 2025 amount, according to the preliminary purchase price allocation, are as follows:
| Fair value | Total |
| Intangible non-current assets | 62 |
| Other non-current assets | 14 |
| Inventories | 21 |
| Other current assets | 44 |
| Deferred tax liability/tax asset | -19 |
| Other liabilities | -27 |
| Acquired net assets | 95 |
| Goodwill | 166 |
| Consideration¹ | 261 |
| Less: | |
| Cash and cash equivalents in acquired businesses | -21 |
| Contingent consideration not yet paid | -54 |
| Holdback | -48 |
| Effect on the Group’s cash and cash equivalents | 138 |
| ¹The consideration is stated excluding acquisition expenses. |
Acquired companies
The purchase price allocations are preliminary as the net assets of the acquired companies have not yet been finally analyzed. For this year’s acquisition, the purchase considerations have exceeded the carrying amounts of the net assets in the acquired companies, resulting in the recognition of intangible assets in the purchase price allocations.
Goodwill
The goodwill arising from the acquisition is attributable to the expectation that the Group’s position in the relevant market will be strengthened, as well as the expertise developed in the acquired companies.
Contingent consideration
The total undiscounted contingent consideration for the acquired company during the year may amount to a maximum of SEK 116m over the next four years. The outcome of contingent considerations is determined by the future earnings reached by the companies and is subject to a fixed maximum level.
Contingent considerations from acquisitions in previous years have been paid out during the interim period in the amount of SEK 51m, relating to DACH Medical, BonsaiLab, and Emmat Medical.
Holdback
Part of the purchase price withheld by the buyer as security for potential claims against the seller, will be paid to the seller according to the agreed payment plan. The withheld parts of the purchase price are independent of conditions linked to the future performance of the acquired companies.
Transaction costs
Transaction costs for acquisitions amount to a total of SEK 8m and are recognized in selling expenses.
Revenue and profit in the acquired company
The acquisition completed during the year have, from the acquisition date, in total affected the Group’s net sales by SEK 24m and EBITA by SEK 7m.
If the acquired company in 2025 had been consolidated as of January 1, 2025, net sales and EBITA would have been estimated at SEK 47m and SEK 10m, respectively.
Acquisitions after the end of the interim period
No acquisitions have been completed after the end of the interim period.